Cyllene Therapeutics (formerly EG 427) develops targeted neurotherapeutics using its proprietary HERMES non-replicating HSV-1 vector platform. Its lead candidate, EG110A, is a DNA medicine being developed for multiple severe bladder diseases, including neurogenic detrusor overactivity (NDO) related to spinal cord injury. Ongoing studies have shown substantial and sustained reductions in urinary incontinence episodes for at least nine months post-treatment in patients with spinal cord injury–related NDO. The company plans a Phase 2b/3 study of EG110A in 2027 and intends to expand into overactive bladder and other neurological indications such as pain and migraine. Cyllene recently completed a €33 million Series C financing to fund these clinical and platform-expansion efforts. The company highlights its position as a leader in non-replicating HSV-1 vector technology in neurology.

Total raised

$89M

Funding rounds

4

Latest round

Series C

Latest activity

Jul 2026